Login to Your Account

Vasogen’s Celacade Misses In Shortened Study Of PAD

By Jennifer Boggs

Tuesday, March 14, 2006
Nearly seven months after the early closeout of the pivotal Phase III study of Celacade in peripheral arterial disease, Vasogen Inc. reported that the product missed its primary endpoint in improving patients’ walking distance over placebo. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription